Journey Medical Corporation Form 8-K Summary
Business Context and Reporting Period
Journey Medical Corporation filed a Current Report on Form 8-K dated May 16, 2023. The filing primarily reports an amendment to the company’s credit facility with East West Bank and references a May 22, 2023 press release announcing results for the three months ended March 31, 2023. The filing text provided does not include the detailed financial results from that press release.
Material Financing Changes
- The company and its subsidiary, JG Pharma, Inc., amended the East West Bank Loan and Security Agreement on May 16, 2023.
- The original facility included a $7.5 million line of credit. In January 2022, borrowing capacity was increased to a $10.0 million revolving line of credit plus a term loan of up to $20.0 million.
- The company had borrowed the full $20.0 million term loan.
- At closing of the amendment, the company agreed to repay $10.0 million of the term loan. The filing does not clearly state the remaining principal balance after repayment.
- The term loan maturity date was accelerated from January 12, 2026 to July 1, 2024.
- The company is no longer required to make monthly principal installments and instead must make interest-only payments until maturity, when all outstanding principal and accrued unpaid interest are due.
- The company may prepay the term loan in whole or in part without penalty or premium, but may not re-borrow amounts repaid.
- The revolving line of credit was removed effective upon the amendment. No amounts were outstanding under the revolver at that time.
Liquidity, Covenants, and Financial Obligations
- Most financial covenants, including collateral ratio requirements, were removed. The minimum liquidity covenant remains in effect, along with certain additional nonfinancial covenants.
- To satisfy the minimum liquidity requirement, the company must maintain $8.75 million in assigned deposit accounts at East West Bank through August 31, 2023.
- Beginning August 31, 2023, the required assigned deposit balance increases to $10.0 million.
- The amended term loan represents a material short-term refinancing and liquidity obligation because the remaining balance is due on July 1, 2024.
Results, Outlook, and Risks
The filing states that a May 22, 2023 press release provided a corporate update and announced financial results for the quarter ended March 31, 2023. The supplied filing text does not provide clear values for revenue, profit or loss, cash flow, margins, cash balances, debt balances after repayment, guidance, or management’s operating outlook.
- Key risks include the accelerated term-loan maturity, the requirement to maintain restricted or assigned cash deposits, and the need to fund the remaining principal and accrued interest by July 1, 2024.
- The filing does not identify any penalty for voluntary prepayment, but repaid amounts cannot be re-borrowed.
Investor Verification Items
- Verify the $10.0 million term-loan repayment and the remaining outstanding principal balance.
- Review the May 22, 2023 press release for the March 31, 2023 revenue, earnings, cash-flow, liquidity, and guidance details.
- Assess the company’s ability to maintain the required $8.75 million, increasing to $10.0 million, in assigned deposits.
- Evaluate the sources of repayment for the term loan due July 1, 2024.
- Review the amendment’s nonfinancial covenants and potential consequences of noncompliance.